The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwHRMM 2025 | The future of in vivo CAR T-cell therapy
In this video, Karlo Perica, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, briefly discusses the future of in vivo CAR T-cell therapy for multiple myeloma (MM) and other diseases, noting that early reports are promising and that several trial readouts are expected in the coming years. Dr Perica highlights that early enthusiasm should be tempered until more results are available and safety data have matured. This interview took place at the 2nd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2025), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So this is a very exciting time, I think particularly in the in vivo space. We certainly expect over the next year or two to see several reports, readouts of trials both in autoimmunity and in myeloma of patients treated with in vivo CAR T-cells. We’re sort of starting to see the first trickle of reports come out. I caution that it is usually the trials that happen to have the earliest successes that get read out first...
So this is a very exciting time, I think particularly in the in vivo space. We certainly expect over the next year or two to see several reports, readouts of trials both in autoimmunity and in myeloma of patients treated with in vivo CAR T-cells. We’re sort of starting to see the first trickle of reports come out. I caution that it is usually the trials that happen to have the earliest successes that get read out first. So we really need to temper our enthusiasm and wait for these results to come out over the next year or two to see more patients treated, to wait for safety signals to mature. There are definitely safety concerns and considerations with some of these products. But despite saying all that, I’m very, very excited that maybe in the next year or two, we’re going to really have a sense of whether these technologies are tractable, viable, if there’s something that’s just going to be a scientific curiosity, if it’s something that we’re actually going to be able to bring widely to patients. And certainly, you know, the field writ large, including biotech, seems to really think that there’s a chance that this will translate to the clinic with some very significant recent investments in these early-stage technologies by major companies. So certainly the early data looks promising and we’re all very excited.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
